Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Supernus Pharmaceuticals, Inc. - Common Stock (NQ:SUPN)

49.28 -0.24 (-0.48%)
Streaming Delayed Price Updated: 12:01 PM EDT, Mar 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Supernus Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
3 Russell 2000 Stocks Walking a Fine Line
The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies often come with higher... 
Via StockStory
News headline image
Supernus to Participate in the 2025 Jefferies Global Healthcare Conference in London
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
5 Must-Read Analyst Questions From Supernus Pharmaceuticals’s Q3 Earnings Call
Supernus Pharmaceuticals reported Q3 results that were above Wall Street’s revenue and profit expectations, but the market reacted negatively, reflecting concerns over execution challenges and forward... 
Via StockStory
Topics Earnings
News headline image
Earnings Scheduled For November 4, 2025 ↗
 
Via Benzinga
News headline image
A Preview Of Supernus Pharmaceuticals's Earnings ↗
 
Via Benzinga
News headline image
Why Supernus Pharmaceuticals (SUPN) Shares Are Trading Lower Today
Shares of specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) fell 16.8% in the morning session after the company's third-quarter 2025 earnings report, as a weak full-year forecast... 
Via StockStory
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
SUPN Q3 Deep Dive: Growth Drivers Offset By Supply Constraints and Integration Costs
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) announced better-than-expected revenue in Q3 CY2025, with sales up 9.3% year on year to $192.1 million. On the other hand, the... 
Via StockStory
Topics Supply Chain
News headline image
Supernus Pharmaceuticals (NASDAQ:SUPN) Surprises With Strong Q3
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) reported Q3 CY2025 results exceeding the market’s revenue expectations, with sales up 9.3% year on year to $192.1 million. On the... 
Via StockStory
News headline image
Supernus Announces Third Quarter 2025 Financial Results
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Spotting Winners: Royalty Pharma (NASDAQ:RPRX) And Branded Pharmaceuticals Stocks In Q2
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Royalty Pharma (NASDAQ:RPRX) and the best... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Supernus Pharmaceuticals (SUPN) Reports Q3: Everything You Need To Know Ahead Of Earnings
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) will be reporting earnings this Tuesday after market hours. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence
News headline image
3 Cash-Producing Stocks That Fall Short
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. 
Via StockStory
News headline image
Supernus Pharmaceuticals Inc (NASDAQ:SUPN) Emerges as a Top Affordable Growth Candidate ↗
Supernus Pharmaceuticals (SUPN) offers affordable growth with strong EPS, solid financials, and a low P/E ratio, making it a compelling investment opportunity. 
Via Chartmill
News headline image
Deep Dive Into Supernus Pharmaceuticals Stock: Analyst Perspectives (5 Ratings) ↗
 
Via Benzinga
News headline image
3 Small-Cap Stocks We’re Skeptical Of
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small... 
Via StockStory
News headline image
Supernus Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
3 Stocks Under $50 We Steer Clear Of
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to... 
Via StockStory
News headline image
SUPERNUS PHARMACEUTICALS INC (NASDAQ:SUPN) Presents a Compelling Mix of Growth and Technical Momentum ↗
Supernus Pharmaceuticals (SUPN) is a strong growth stock with a debt-free balance sheet and a positive technical breakout pattern. Explore its potential. 
Via Chartmill
News headline image
Branded Pharmaceuticals Stocks Q2 Earnings Review: Supernus Pharmaceuticals (NASDAQ:SUPN) Shines
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, including Supernus Pharmaceuticals (NASDAQ:SUPN)... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Supernus Pharmaceuticals (SUPN) Stock Is Up, What You Need To Know
Shares of specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) jumped 4.6% in the morning session after Piper Sandler upgraded the company's stock from a "Neutral" to an "Overweight"... 
Via StockStory
Topics Artificial Intelligence
News headline image
Crowdstrike To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Thursday ↗
 
Via Benzinga
News headline image
Q2 Earnings Highs And Lows: Organon (NYSE:OGN) Vs The Rest Of The Branded Pharmaceuticals Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Organon (NYSE:OGN) and the best and worst... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
SUPERNUS PHARMACEUTICALS INC (NASDAQ:SUPN) Represents an Affordable Growth Opportunity ↗
Supernus Pharmaceuticals (SUPN) offers affordable growth with strong earnings, a clean balance sheet, and an attractive P/E ratio below industry peers. 
Via Chartmill
News headline image
Pharma ETFs In A Tariff Storm: How Investors Can Hedge Risk ↗
The U.S. pharmaceutical industry is at the center of a policy maelstrom. 
Via Benzinga
Topics ETFs
News headline image
Branded Pharmaceuticals Stocks Q2 Highlights: Collegium Pharmaceutical (NASDAQ:COLL)
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Collegium Pharmaceutical... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Biogen Receives European Commission Approval for ZURZUVAE® (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe
From Biogen Inc.
Via GlobeNewswire
News headline image
3 Overrated Stocks with Questionable Fundamentals
Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements, or favorable market conditions. 
Via StockStory
News headline image
SUPERNUS PHARMACEUTICALS INC (NASDAQ:SUPN) Emerges as a Top Affordable Growth Stock ↗
SUPERNUS (SUPN) offers affordable growth with strong EPS & revenue expansion, solid profitability, and a sound financial base, all at a discount to the pharmaceutical industry. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.